UNBS 5162 is in a Phase I study for solid tumors and lymphoma.

Drais Pharmaceuticals licensed Unibioscreen’s early-stage cancer drug in a deal valued at over $31 million. The agreement grants Drais exclusive rights to develop and commercialize UNBS 5162 worldwide.

The $31 million covers an upfront payment as well as development and regulatory milestones fees. Drais will also pay milestones dependant on commercialization.

UNBS 5162 is a naphthalimide in Phase I trials for the treatment of solid tumors and lymphoma.

Previous articleFDA Asks for Risk-Mitigation Strategy before Sanctioning Cephalon’s Opioid for Noncancer-Related Pain
Next articleMutation In Single Copy of APC Gene Heightens Risk of Developing Colon Cancer